Details for Patent: 11,040,029
✉ Email this page to a colleague
Which drugs does patent 11,040,029 protect, and when does it expire?
Patent 11,040,029 protects INGREZZA and is included in one NDA.
This patent has seventy patent family members in eleven countries.
Summary for Patent: 11,040,029
| Title: | Methods for the administration of certain VMAT2 inhibitors |
| Abstract: | Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-.alpha.-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2- ,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient is also being administered a strong cytochrome P450 2D6 (CYP2D6) inhibitor. |
| Inventor(s): | O'Brien; Christopher F. (San Diego, CA), Bozigian; Haig P. (San Diego, CA) |
| Assignee: | Neurocrine Biosciences, Inc. (San Diego, CA) |
| Application Number: | 16/870,572 |
|
Patent Claim Types: see list of patent claims | Use; Dosage form; |
Recent additions to Drugs Protected by US Patent 11,040,029
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neurocrine | INGREZZA SPRINKLE | valbenazine tosylate | CAPSULE | 218390 | Apr 30, 2024 | RX | Yes | ⤷ Sign Up | ⤷ Sign Up | U-1995 | TREATMENT OF TARDIVE DYSKINESIA | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 11,040,029
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-001 | Apr 11, 2017 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF TARDIVE DYSKINESIA | ⤷ Sign Up | |||
| Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-003 | Apr 23, 2021 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF TARDIVE DYSKINESIA | ⤷ Sign Up | ||||
| Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-002 | Oct 4, 2017 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF TARDIVE DYSKINESIA | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,040,029
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2017395700 | ⤷ Sign Up | |||
| Australia | 2017395701 | ⤷ Sign Up | |||
| Australia | 2017395702 | ⤷ Sign Up | |||
| Australia | 2017395703 | ⤷ Sign Up | |||
| Australia | 2017395704 | ⤷ Sign Up | |||
| Australia | 2022203201 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
